The Citalopram for Agitation in Alzheimer Disease Study (CitAD) randomized 186 AD patients with clinically significant agitation to psychosocial intervention with or without citalopram 30 mg/day for nine weeks (Porsteinsson et al. JAMA 2014;311:682-691). The dose of citalopram was titrated from 10 mg/day to the planned dose of 30 mg/day over three weeks.